BioSig Technologies to Participate in the B Riley FBR Virtual Infectious Disease Summit
BioSig Technologies (BSGM) announced Jerry Zeldis, CMO of its subsidiary ViralClear Pharmaceuticals, will speak at the B Riley FBR Infectious Disease Summit on July 21, 2020. The summit focuses on therapeutics for infectious diseases, including COVID-19, and Zeldis will participate in the "Arresting the Viral Replication Cycle" panel at 1:15 PM ET.
ViralClear is developing merimepodib, a novel treatment for COVID-19, which has shown strong antiviral activity against SARS-CoV-2. The company aims to enhance signal fidelity in medical procedures through its proprietary platform.
- None.
- None.
Westport, CT, July 17, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Jerry Zeldis, M.D., Ph.D., Chief Medical Officer of ViralClear Pharmaceuticals, Inc. , a majority owned subsidiary of BioSig, will be participating in the B Riley FBR Infectious Disease Summit -- Part III: Therapeutics “Fast and Curious: Race to Finding Cures for Several Infectious Diseases, Including COVID-19” on July 21, 2020. The panel segment is “Arresting the Viral Replication Cycle.”
Speaking Information:
Event: B. Riley FBR Virtual Infectious Disease Summit - Part III: Therapeutics “Fast and Curious: Race to Finding Cures for Several Infectious Diseases, Including COVID-19”
Panel: Arresting the Viral Replication Cycle
Date: Tuesday, July 21, 2020
Time: 1:15 PM ET
If you are an institutional investor and would like to attend the event, please contact Andrew Ballou, Vice President, Investor Relations at aballou@biosigtech.com.
About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.
About ViralClear Pharmaceuticals, Inc. and Merimepodib (MMPD)
BioSig Technologies, Inc.’s (BSGM) subsidiary, ViralClear Pharmaceuticals, Inc., is seeking to develop a novel pharmaceutical called merimepodib to treat patients with COVID-19. Merimepodib is intended to be orally administered, and has demonstrated broad-spectrum in vitro antiviral activity, including strong activity against SARS-CoV-2 in cell cultures. Merimepodib was previously in development as a treatment for chronic hepatitis C and psoriasis by Vertex Pharmaceuticals Incorporated (Vertex), with 12 clinical trials (7 in phase 1 and 5 in phase 2) with over 400 subjects and patients and an extensive preclinical safety package was completed. A manuscript titled, “The IMPDH inhibitor merimepodib provided in combination with the adenosine analogue remdesivir reduces SARS-CoV-2 replication to undetectable levels in vitro”, was submitted to an online peer-reviewed life sciences journal. This manuscript is authored by Natalya Bukreyeva, Rachel A. Sattler, Emily K. Mantlo, John T. Manning, Cheng Huang and Slobodan Paessler of the UTMB Galveston National Laboratory and Dr. Jerome Zeldis of ViralClear Pharmaceuticals, Inc. (“ViralClear”) as a corresponding author. This article highlights pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 54 Wilton Road, 2nd floor Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133
FAQ
When is Jerry Zeldis speaking at the B Riley FBR Infectious Disease Summit?
What is the focus of the panel that Jerry Zeldis will participate in?
What is merimepodib and its significance related to COVID-19?
What does BioSig Technologies' signal processing platform aim to improve?
